Here’s a roundup of the latest dealflow and investment news:
- Online physician community Sermo drums up $5 million
MMV Financial, a specialty finance firm serving venture-backed companies in North America, announced today that it has extended $3.5 million in growth capital financing to Sermo Inc., the largest online physician community in the United States. The financing, part of a larger $5 million facility for Sermo, will allow the company to continue expanding its physician community while serving a growing roster of over 300 clients. Founded in 2005, Sermo is a resource for any organization in need of dependable physician feedback. The company’s platform is designed to allow clients to aggregate information, tap into peer-to-peer insight, gain market intelligence and increase brand awareness.
Read more - Nephros commences rights offering
Nephros Inc. (OTC:NEPH), a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that the materials for its previously announced rights offering to its existing stockholders have been distributed. Under the terms of the rights offering described in the prospectus related to the rights offering, Nephros is distributing at no charge non-transferable subscription rights to purchase up to an aggregate of 175,000,000 units to stockholders who owned shares of Nephros common stock as of the close of business on Jan. 31, 2011, which is the record date for the rights offering.
Read more - VisionScope reels in $6.3 million
VisionScope Technologies LLC closed a $6.3 million round. The Concord, Mass.-based arthroscopic medical device maker’s new equity-based financing was sourced from 27 investors.
Read more - Flagship Ventures’ success in life science grows with "VentureLabs"
Flagship VentureLabs has created 24 companies in the life sciences and cleantech sectors, several of which have gone public, been acquired, or risen to notable success. Many of the names are well-known in the Boston life sciences and cleantech communities and beyond, writes Xconomy Boston.
Read more
